About
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportDiscover how The US Oncology Network leverages AI to reduce provider burden, extract clinical data and improve patient outcomes.
By: Mudasser Zaheer, SVP and CIO, Oncology & Multispecialty, McKesson
Read Time
4 minutes
With four out of five community oncologists expecting AI to play an essential role in clinical and administrative functions, The US Oncology Network (The Network), supported by McKesson’s deep expertise and resources, is leading the charge in developing AI solutions tailored for community oncology. By proactively harnessing cutting-edge AI technologies, we are advancing value-based care, reducing provider burden and improving patient outcomes. These innovations also open the door to broader collaboration across the healthcare ecosystem in community practices, benefiting key stakeholders and enabling biopharma to support research and expand access to care.
As leaders in community oncology, we are uniquely positioned to help providers accelerate research, streamline operations and expand access to care through AI. The following examples highlight how our AI programs and guiding philosophy are rooted in a commitment to advancing patient care and improving outcomes.
In collaboration with McKesson, The Network has made significant investments in adapting AI technologies to meet the unique needs of community oncology. These efforts are focused on creating operational efficiencies, reducing provider burden and burnout and enabling physicians to spend more time with their patients. These are some of the most promising applications:
These innovations are already making a tangible impact on care delivery. By embedding AI into everyday workflows, we’re helping community oncology practices operate more efficiently and deliver more personalized, patient-centered care. In parallel, these advancements also support broader collaboration across the healthcare landscape — enabling more inclusive research, improving data quality and fostering new models of care that benefit all stakeholders.
Our guiding principle is clear: AI will never replace the provider. Instead, it will amplify clinical intuition, reduce administrative burden and help clinicians focus more fully on their patients.
While AI holds immense promise for improving cancer care, we recognize the importance of using this technology responsibly. At The Network, we view AI not simply as a tool but as a trusted partner that can help clinicians deliver smarter, more personalized care — without compromising the human connection at the heart of oncology.
To ensure our approach remains grounded in ethics and transparency, we established The AI Council, a multidisciplinary group of care team members dedicated to evaluating and guiding the use of AI across The Network. Their mission is to explore opportunities where AI can meaningfully enhance the patient experience and support care delivery while upholding our core values of trust, equity and accountability.
Our guiding principle is clear: AI will never replace the provider. Instead, it will amplify clinical intuition, reduce administrative burden and help clinicians focus more fully on their patients. We are building a future where technology supports — not supplants — the human touch that defines community oncology.
Adopting artificial intelligence in healthcare is not without its challenges — but community oncologists are embracing the opportunity because of the meaningful benefits it brings to their practices and patients. At The Network, we are proud to be at the forefront of integrating AI into community settings, with a clear focus on alleviating the administrative and operational burdens that often limit the time providers can spend with their patients.
Beyond The Network, McKesson continues to embed AI across a range of solutions that support community oncology practices. These include tools that optimize specialty therapy workflows, streamline inventory management, enhance contract negotiations and reduce administrative friction related to payer denials. Each of these innovations is designed with a singular goal: to help providers focus more time and energy on delivering high-quality, compassionate care.
Our commitment is unwavering: to harness AI and other transformative technologies in ways that empower community oncologists to focus on what matters most — caring for their patients.
1National Institutes of Health. Incidence rates of some cancer types have risen in people under age 50. National Cancer Institute Press Office. May 8, 2025. Accessed October 2025.
Learn how we help accelerate innovative therapy launches so providers can access them when and where patients need them most.
Biopharma and community oncology must unite in a new patient reality.
Anthony Gonzalez, BSN, RN, travels the U.S. to help physicians deliver specialty infusion services in their offices, keeping patients close to home and on track with treatment.
At Biologics by McKesson, proactive pharmacy care and personalized support help patients stay on therapies, reduce costs and improve outcomes.
How McKesson connects biopharma, providers and patients to deliver precision oncology at scale through integrated logistics, specialty pharmacy and high‑touch support.
Sarah Cannon Research Institute (SCRI) offers clinical trials in communities close to home, where 85% of patients seek care.
How community oncology clinics are helping break down barriers to care.
In the third episode of our Always Advancing video series, learn how precision and personalized medicine are transforming cancer care – expanding access to clinical trials and novel treatments in communities.
Using McKesson Compile’s analytics to transform how patients with rare blood disorders access specialized care across Indiana.
InspiroGene by McKesson helps patients with rare and severe diseases access innovative cell and gene therapies through personalized support at every step of their journey.